Takeda Pharmaceutical Company Limited 보도자료

12월 6일 10:45

Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners

Takeda (TSE:4502/NYSE:TAK ) and The New York Academy of Sciences today announced the winners of the 2024 Innovators in Science Award for their excellence in, and commitment to, innovative science that has significantly advanced the field of resear...

건강 제약 수상/선정

11월 10일 17:40

Takeda Receives U.S. FDA Approval of FRUZAQLA™ for Previously Treated Metastatic Colorectal Cancer

Takeda (TSE:4502/NYSE:TAK ) today announced that the U.S. Food and Drug Administration (FDA) has approved FRUZAQLA™ (fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have been previously treated with ...

건강 제약 개발

11월 10일 17:40

다케다, 치료 전력 있는 전이성 대장암 환자 치료제로 FRUZAQLA™에 대한 미국 식품의약국 승인 획득

다케다(Takeda)(도쿄증권거래소: 4502/뉴욕증권거래소: TAK )는 오늘 미국 식품의약국(FDA)이 FRUZAQLA™(프루킨티닙)를 승인했다고 발표했다. 프루자클라는 플루오로피리미딘(fluoropyrimidine-), 옥살리플라틴(oxaliplatin-), 이리노테칸(irinotecan-) 기반 화학요...

건강 제약 개발

11월 10일 11:15

Takeda’s ADZYNMA Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura

Takeda (TSE:4502/NYSE:TAK ) today announced that the U.S. Food and Drug Administration (FDA) has approved ADZYNMA (ADAMTS13, recombinant-krhn) for the prophylactic and on-demand treatment of adult and pediatric patients with congenital thrombotic ...

건강 제약 의학 개발

11월 8일 10:48

Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting

Takeda (TSE:4502/NYSE:TAK) today announced that the company will present positive results from its randomized, double-blind, placebo-controlled, Phase 2b trial evaluating TAK-279, an investigational oral allosteric tyrosine kinase 2 (TYK2) inhibit...

건강 제약 병원/의료 조사연구

10월 27일 11:40

Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance

Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the first half of fiscal year 2023 (six months ended September 30, 2023), updating reported and Core forecasts and reconfirming Management Guidance for Core change at CER. Takeda c...

건강 제약 실적

10월 27일 11:40

다케다, 회계연도 2023년 상반기 실적 발표… 경영 지침 준수하며 연간 전망 수정

다케다(Takeda)(도쿄증권거래소: 4502/뉴욕증권거래소: TAK)가 오늘 회계연도 2023년 상반기(2023년 9월 30일에 마감된 6개월) 재무 실적을 발표하며, 보고 및 핵심 전망치를 조정하고 CER 기준 핵심 변경 사항에 대한 경영 지침을 재확인했다. 다케다 최고경영자인 ...

건강 제약 실적

10월 19일 10:55

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

Takeda (TSE:4502/NYSE:TAK ) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine (AVD) to treat adult patients with previously untreated CD30+ Stage...

건강 제약 병원/의료 개발

10월 18일 15:30

Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas

Takeda (TSE:4502/NYSE: TAK) today announced that the Phase 3 ADMIRE-CD II study, assessing the efficacy and safety of Alofisel® (darvadstrocel) for the treatment of complex Crohn’s Perianal Fistulas (CPF), did not meet its primary endpoint of comb...

건강 제약 병원/의료 조사연구

10월 18일 14:54

Takeda Settles Tax Dispute with Irish Revenue over Break Fee Received by Shire

Takeda (TSE:4502/NYSE:TAK ) today announced that, on October 17, 2023 (IST), it agreed with the Irish Revenue Commissioners (“Irish Revenue”) to settle a tax assessment related to the treatment of an acquisition break fee received by Shire plc (“S...

건강 제약 경제 회계/세무 사업계획

10월 6일 14:30

Takeda’s Dengue Vaccine Recommended by World Health Organization Advisory Group for Introduction in High Dengue Burden and Transmission Areas in Children Ages Six to 16 Years

Takeda (TSE:4502/NYSE:TAK ) today announced that the World Health Organization’s (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization shared recommendations for use of QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003)....

건강 제약 병원/의료 사업계획

10월 6일 14:30

다케다 뎅기열 백신, 세계보건기구 자문단의 고위험 및 전파 지역 6~16세 아동 및 청소년 대상 접종 권고

다케다(Takeda) (도쿄증권거래소:4502/뉴욕증권거래소:TAK )가 세계보건기구(WHO)의 예방 접종 전략자문전문가그룹(SAGE)이 QDENGA®▼ (뎅기열 4가 백신 [약독성 생백신])(TAK-003) 사용에 관한 권고안 을 공유했다고 발표했다. 수개월 내 WHO는 SAGE 권고안을 검토하...

건강 제약 병원/의료 사업계획

10월 4일 11:10

Takeda Provides Update on EXKIVITY® (mobocertinib)

Takeda (TSE:4502/NYSE:TAK ) today announced that, following discussions with the U.S. Food and Drug Administration (FDA), it will be working with the FDA towards a voluntary withdrawal of EXKIVITY® (mobocertinib) in the U.S. for adult patients wit...

건강 제약 병원/의료 사업계획

10월 4일 11:10

다케다, EXKIVITY®에 대한 업데이트 발표

다케다(Takeda)(도쿄증권거래소:4502/뉴욕증권거래소:TAK )는 오늘 백금 기반 화학요법 도중 또는 이후에 질병이 진행된 표피성장인자수용체(EGFR) Exon20 삽입 돌연변이 양성(삽입+) 국소 진행성 또는 전이성 비소세포폐암(NSCLC) 성인 환자에 대한 미국 내 EXKIVIT...

건강 제약 사업계획

9월 26일 11:25

Takeda Announces Approval of CUVITRU™ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda (TSE:4502/NYSE:TAK ) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of CUVITRU™ [Immune Globulin Subcutaneous (Human), 20% Solution] in patients aged 2 years and older with agammaglobulinemia o...

건강 제약 병원/의료 개발

9월 20일 09:55

Takeda Commits Over $30 Million in Five New Global CSR Partnerships To Further Drive Health Impact in 92 Countries

Takeda (TSE:4502/NYSE:TAK ) today announced five new partnerships to its Global Corporate Social Responsibility (CSR) Program, which contribute to strengthening health systems in low- and middle-income countries. The new partnerships bring its tot...

건강 제약 제휴

9월 20일 09:55

다케다, 5개의 신규 글로벌 CSR 파트너십에 3000만달러 이상의 투자로 92개국에서 보건 영향력 확대

다케다(도쿄증권거래소:4502/뉴욕증권거래소:TAK )(Takeda)가 오늘 글로벌 기업의 사회적 책임(Global Corporate Social Responsibility, CSR) 프로그램에 대해 5건의 신규 파트너십을 체결했다고 발표했다. 이 파트너십은 저소득 및 중저소득 국가의 보건 시스템 강...

건강 제약 제휴

9월 12일 09:33

Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis

Takeda (TSE:4502/NYSE:TAK ) today announced positive topline results from its randomized, double-blind, placebo-controlled, multiple-dose Phase 2b trial evaluating TAK-279, an investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor with...

건강 제약 병원/의료 조사연구

7월 30일 11:30

Takeda Reports Strong First Quarter FY2023 Results, Driven by Growth & Launch Products

Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for the first quarter of fiscal year 2023 (period ended June 30, 2023). Takeda chief financial officer, Costa Saroukos, commented: “Our Growth & Launch Products continued to dri...

건강 제약 실적

7월 30일 11:30

다케다, 성장 및 출시 제품에 힘입어 2023년 회계연도 1분기 견조한 실적 발표

오사카, 일본/캠브릿지, 메사추세츠--(Business Wire / 뉴스와이어) 2023년 07월 30일 -- 다케다(Takeda)(도쿄증권거래소: 4502/뉴욕증권거래소: TAK)가 2023년 회계연도 1분기(2023년 6월 30일 마감) 재무실적이 호조를 보였다고 오늘 발표했다. 다케다 최고재무책...

건강 제약 실적

7월 27일 10:35

The New England Journal of Medicine Publishes Data from Phase 2 Study of First Oral Orexin Receptor 2 Agonist TAK-994 in Patients with Narcolepsy Type 1

Takeda (TSE:4502/NYSE:TAK) today announced that data from the Phase 2 study of orexin receptor 2 (OX2R) agonist TAK-994 in patients with narcolepsy type 1 (NT1) was published in The New England Journal of Medicine. These data represent the first-e...

건강 제약 병원/의료 조사연구

6월 26일 09:00

Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda (TSE: 4502/NYSE:TAK) today presented favorable interim results from a global pivotal Phase 3 randomized, controlled, open-label, crossover trial evaluating the safety and efficacy of TAK-755 (recombinant ADAMTS13) replacement therapy for th...

건강 제약 병원/의료 조사연구

6월 21일 11:30

Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting

Takeda (TSE:4502/NYSE:TAK) today announced full results from the pivotal Phase 3 ADVANCE-CIDP 1 clinical trial investigating HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] as maintenance therapy in adult patien...

건강 제약 조사연구

6월 21일 11:30

다케다, PNS 연례 회의에서 만성 염증성 탈수초성 다발신경병증의 유지 요법으로 HYQVIA®를 조사하는 제3상 ADVANCE-CIDP 1 임상시험의 전체 데이터 세트 발표

다케다(TSE:4502/NYSE:TAK)는 오늘 만성 염증성 탈수초성 다발신경병증(CIDP)이 있는 성인 환자의 유지 요법으로 하이큐비아(HYQVIA®)(재조합 인간 히알루로니다아제를 사용한 면역 글로불린 주입 10%(인간))를 조사하는 중추적 3상 ADVANCE-CIDP 1 임상 시험의 전체...

건강 제약 조사연구

6월 18일 14:00

Takeda and HUTCHMED Announce Publication of Phase 3 FRESCO-2 Results in The Lancet

Takeda (TSE:4502/NYSE:TAK) and HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (HUTCHMED) today announced that results of the Phase 3 FRESCO2 study evaluating fruquintinib in patients with previously treated metastatic colorectal cancer (CRC) w...

건강 제약 의학 조사연구

Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited 보도자료

Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners

Takeda Receives U.S. FDA Approval of FRUZAQLA™ for Previously Treated Metastatic Colorectal Cancer

다케다, 치료 전력 있는 전이성 대장암 환자 치료제로 FRUZAQLA™에 대한 미국 식품의약국 승인 획득

Takeda’s ADZYNMA Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura

Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting

Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance

다케다, 회계연도 2023년 상반기 실적 발표… 경영 지침 준수하며 연간 전망 수정

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas

Takeda Settles Tax Dispute with Irish Revenue over Break Fee Received by Shire

Takeda’s Dengue Vaccine Recommended by World Health Organization Advisory Group for Introduction in High Dengue Burden and Transmission Areas in Children Ages Six to 16 Years

다케다 뎅기열 백신, 세계보건기구 자문단의 고위험 및 전파 지역 6~16세 아동 및 청소년 대상 접종 권고

Takeda Provides Update on EXKIVITY® (mobocertinib)

다케다, EXKIVITY®에 대한 업데이트 발표

Takeda Announces Approval of CUVITRU™ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda Commits Over $30 Million in Five New Global CSR Partnerships To Further Drive Health Impact in 92 Countries

다케다, 5개의 신규 글로벌 CSR 파트너십에 3000만달러 이상의 투자로 92개국에서 보건 영향력 확대

Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis

Takeda Reports Strong First Quarter FY2023 Results, Driven by Growth & Launch Products

다케다, 성장 및 출시 제품에 힘입어 2023년 회계연도 1분기 견조한 실적 발표

The New England Journal of Medicine Publishes Data from Phase 2 Study of First Oral Orexin Receptor 2 Agonist TAK-994 in Patients with Narcolepsy Type 1

Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting

다케다, PNS 연례 회의에서 만성 염증성 탈수초성 다발신경병증의 유지 요법으로 HYQVIA®를 조사하는 제3상 ADVANCE-CIDP 1 임상시험의 전체 데이터 세트 발표

Takeda and HUTCHMED Announce Publication of Phase 3 FRESCO-2 Results in The Lancet

동영상

회사 보도자료 구독